{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:23:30Z","timestamp":1778617410102,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.bbrc.2020.04.096","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:32Z","timestamp":1588118432000},"page":"167-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["N-p-Tosyl-L-phenylalanine chloromethyl ketone (TPCK) inhibits HIV-1 by suppressing the activity of viral protease"],"prefix":"10.1016","volume":"527","author":[{"given":"Jay","family":"Trivedi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Payel","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5272-5407","authenticated-orcid":false,"given":"Debashis","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbrc.2020.04.096_bib1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2215\/CJN.02240218","article-title":"Clinical pharmacology in HIV therapy","volume":"14","author":"Atta","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bbrc.2020.04.096_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev-med-041217-013717","article-title":"Long-acting HIV drugs for treatment and prevention","volume":"70","author":"Gulick","year":"2019","journal-title":"Annu. Rev. Med."},{"issue":"11","key":"10.1016\/j.bbrc.2020.04.096_bib3","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1080\/13543784.2017.1378643","article-title":"Investigational HIV integrase inhibitors in phase I and phase II clinical trials","volume":"26","author":"Han","year":"2017","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"7","key":"10.1016\/j.bbrc.2020.04.096_bib4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.tim.2019.02.009","article-title":"The promise of long-acting antiretroviral therapies: from need to manufacture","volume":"27","author":"Gendelman","year":"2019","journal-title":"Trends Microbiol."},{"issue":"10","key":"10.1016\/j.bbrc.2020.04.096_bib5","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1021\/acs.jmedchem.8b00843","article-title":"The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic","volume":"62","author":"Namasivayam","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"issue":"3","key":"10.1016\/j.bbrc.2020.04.096_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.bbrc.2020.04.096_bib7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrd4650","article-title":"Improving R&D productivity","volume":"14","author":"Smietana","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.bbrc.2020.04.096_bib8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.tim.2018.04.004","article-title":"Drug repurposing for viral infectious diseases: how far are we?","volume":"26","author":"Mercorelli","year":"2018","journal-title":"Trends Microbiol."},{"issue":"531","key":"10.1016\/j.bbrc.2020.04.096_bib9","article-title":"Drug repurposing approaches for the treatment of influenza viral infection: reviving old drugs to fight against a long-lived enemy","volume":"10","author":"Pizzorno","year":"2019","journal-title":"Front. Immunol."},{"issue":"30","key":"10.1016\/j.bbrc.2020.04.096_bib10","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1021\/bi900660f","article-title":"N-tosyl-L-phenylalanine chloromethyl ketone inhibits NF-kappaB activation by blocking specific cysteine residues of IkappaB kinase beta and p65\/RelA","volume":"48","author":"Ha","year":"2009","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.bbrc.2020.04.096_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/cbir.1999.0469","article-title":"Effect of the serine protease inhibitor N-tosyl-l-phenylalanine-chloromethyl ketone (TPCK) on MCF-7 mammary tumour cells growth and differentiation","volume":"24","author":"Holmes","year":"2000","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.bbrc.2020.04.096_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1742-6405-7-26","article-title":"Alkylating HIV-1 Nef - a potential way of HIV intervention","volume":"7","author":"Jin","year":"2010","journal-title":"AIDS Res. Ther."},{"issue":"1","key":"10.1016\/j.bbrc.2020.04.096_bib13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1006\/cimm.1994.1115","article-title":"Effect of serine protease inhibitor, N-alpha-tosyl-L-lysyl-chloromethyl ketone (TLCK), on cell-mediated and cell-free HIV-1 spread","volume":"155","author":"Bourinbaiar","year":"1994","journal-title":"Cell. Immunol."},{"issue":"13","key":"10.1016\/j.bbrc.2020.04.096_bib14","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1074\/jbc.M116.765842","article-title":"Cyclin F\/FBXO1 interacts with HIV-1 viral infectivity factor (vif) and restricts progeny virion infectivity by ubiquitination and proteasomal degradation of vif protein through SCF(cyclin F) E3 ligase machinery","volume":"292","author":"Augustine","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2020.04.096_bib15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejmech.2018.07.067","article-title":"Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors","volume":"157","author":"Gawali","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bbrc.2020.04.096_bib16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1128\/jvi.59.2.284-291.1986","article-title":"Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone","volume":"59","author":"Adachi","year":"1986","journal-title":"J.\u00a0Virol."},{"issue":"14","key":"10.1016\/j.bbrc.2020.04.096_bib17","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1089\/088922299310223","article-title":"An infectious DNA clone of HIV type 1 subtype C","volume":"15","author":"Mochizuki","year":"1999","journal-title":"AIDS Res. Hum. Retrovir."},{"issue":"16","key":"10.1016\/j.bbrc.2020.04.096_bib18","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J.\u00a0Comput. Chem."},{"issue":"7192","key":"10.1016\/j.bbrc.2020.04.096_bib19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nature06941","article-title":"Dynamic binding orientations direct activity of HIV reverse transcriptase","volume":"453","author":"Abbondanzieri","year":"2008","journal-title":"Nature"},{"issue":"51","key":"10.1016\/j.bbrc.2020.04.096_bib20","doi-asserted-by":"crossref","first-page":"26566","DOI":"10.1074\/jbc.M116.753160","article-title":"HIV-1 reverse transcriptase polymerase and RNase H (ribonuclease H) active sites work simultaneously and independently","volume":"291","author":"Li","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"issue":"3","key":"10.1016\/j.bbrc.2020.04.096_bib21","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1134\/S002689331803007X","article-title":"Mutation frequencies in HIV-1 genome in regions containing efficient RNAi targets as calculated from ultra-deep sequencing data","volume":"52","author":"Kretova","year":"2018","journal-title":"Mol. Biol."},{"issue":"Suppl 2","key":"10.1016\/j.bbrc.2020.04.096_bib22","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1086\/313853","article-title":"HIV-1 protease inhibitors","volume":"30","author":"Eron","year":"2000","journal-title":"Clin. Infect. Dis."},{"issue":"15","key":"10.1016\/j.bbrc.2020.04.096_bib23","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1080\/14656566.2016.1232387","article-title":"Abacavir\u00a0+ dolutegravir\u00a0+ lamivudine for the treatment of HIV","volume":"17","author":"Comi","year":"2016","journal-title":"Expet Opin. Pharmacother."},{"issue":"4","key":"10.1016\/j.bbrc.2020.04.096_bib24","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","article-title":"Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial","volume":"4","author":"Sax","year":"2017","journal-title":"Lancet HIV"},{"issue":"23","key":"10.1016\/j.bbrc.2020.04.096_bib25","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa0906768","article-title":"Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy","volume":"361","author":"Sax","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"4599","key":"10.1016\/j.bbrc.2020.04.096_bib26","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","article-title":"Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).","volume":"220","author":"Barre-Sinoussi","year":"1983","journal-title":"Science"},{"issue":"4599","key":"10.1016\/j.bbrc.2020.04.096_bib27","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1126\/science.6601823","article-title":"Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Gallo","year":"1983","journal-title":"Science"},{"issue":"4664","key":"10.1016\/j.bbrc.2020.04.096_bib28","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1126\/science.6206563","article-title":"Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS","volume":"225","author":"Levy","year":"1984","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bbrc.2020.04.096_bib29","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect. Dis."},{"issue":"5933","key":"10.1016\/j.bbrc.2020.04.096_bib30","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.1169920","article-title":"Drug discovery. Repurposing with a difference","volume":"324","author":"Boguski","year":"2009","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bbrc.2020.04.096_bib31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm.4306","article-title":"The Drug Repurposing Hub: a next-generation drug library and information resource","volume":"23","author":"Corsello","year":"2017","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bbrc.2020.04.096_bib32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.drudis.2012.08.005","article-title":"In silico drug repositioning: what we need to know","volume":"18","author":"Liu","year":"2013","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.bbrc.2020.04.096_bib33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bbrc.2016.02.089","article-title":"Gene expression profiling reveals Nef induced deregulation of lipid metabolism in HIV-1 infected T cells","volume":"472","author":"Shrivastava","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.bbrc.2020.04.096_bib34","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1021\/acs.jmedchem.7b00172","article-title":"Design and development of highly potent HIV-1 protease inhibitors with a crown-like oxotricyclic core as the P2-ligand to combat multidrug-resistant HIV variants","volume":"60","author":"Ghosh","year":"2017","journal-title":"J.\u00a0Med. Chem."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20308226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20308226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:51:54Z","timestamp":1757764314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X20308226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0006291X20308226"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.04.096","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-p-Tosyl-L-phenylalanine chloromethyl ketone (TPCK) inhibits HIV-1 by suppressing the activity of viral protease","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.04.096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}